The addition of the oral phosphodiesterase-5 (PDE-5) inhibitor pentoxifylline to sildenafil failed to show benefit in men with erectile dysfunction (ED) with suboptimal response to sildenafil, a Singapore study shows.
The reduced incidence of breast cancer with 5-year prophylaxis with the aromatase inhibitor anastrozole among women at high risk of the disease persists even after anastrozole cessation, suggests long-term results of the IBIS-II* trial presented at SABCS 2019.
While the SSRI fluoxetine appeared to improve obsessive-compulsive behaviours at 16 weeks compared with placebo in children and adolescents with autism spectrum disorders (ASD) in the initial analysis, the difference between groups became nonsignificant after correcting for potential confounding factors and imbalances in baseline characteristics, reveals the FAB* study.
The addition of tucatinib to a trastuzumab-capecitabine regimen improved progression-free survival (PFS) in patients with HER2+ metastatic breast cancer (MBC) previously treated with multiple HER2-targeted agents, according to the HER2CLIMB* study presented at SABCS** 2019. Additionally, this improved PFS was also noted in patients with brain metastases.
The use of acetaminophen 3 months prior to pregnancy was associated with an increased risk of adverse birth outcomes, such as low birth weight (LBW), preterm birth (PTB), and small-for-gestational-age (SGA), according to a recent study.
In chronic obstructive pulmonary disease (COPD) patients initiating inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, both budesonide/formoterol (FOR) dry-powder inhalers and beclomethasone/FOR metered-dose inhalers pose lower risks of severe pneumonia and severe adverse events compared with fluticasone/salmeterol delivered using the same type of inhaler, as reported in a recent study.
Three anticonvulsant drugs — levetiracetam, fosphenytoin, and valproate — are equally effective in stopping life-threatening epilepsy seizures in patients who are unresponsive to benzodiazepines, thus providing affirmation for physicians that any of the three drugs can be used for treating status epilepticus, according to results from ESETT*.
Older patients and those with haemato-oncology conditions are less likely than surgical patients to be referred to infectious disease (ID) physicians within 48 hours of hospital admission. Furthermore, they appear to be more likely to require antibiotic stewardship programmes (ASP) due to inappropriate type or duration of antibiotic therapy despite ID consultations, a retrospective cross-sectional study from Singapore showed.
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.